Literature DB >> 24291241

Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study.

Jill M Abrigo1, Jiayun Shen2, Vincent W-S Wong2, David K-W Yeung3, Grace L-H Wong2, Angel M-L Chim2, Anthony W-H Chan4, Paul C-L Choi4, Francis K-L Chan2, Henry L-Y Chan5, Winnie C-W Chu6.   

Abstract

BACKGROUND & AIMS: Liver biopsy is the gold standard for diagnosing non-alcoholic fatty liver disease (NAFLD) but with practical constraints. Phosphorus magnetic resonance spectroscopy ((31)P-MRS) allows in vivo assessment of hepatocellular metabolism and has shown potential for biochemical differentiation in diffuse liver disease. Our aims were to describe spectroscopic signatures in biopsy-proven NAFLD and to determine diagnostic performance of (31)P-MRS for non-alcoholic steatohepatitis (NASH).
METHODS: (31)P-MRS was performed in 151 subjects, comprised of healthy controls (n=19) and NAFLD patients with non-NASH (n=37) and NASH (n=95). Signal intensity ratios for phosphomonoesters (PME) including phosphoethanolamine (PE), phosphodiesters (PDE) including glycerophosphocholine (GPC), total nucleotide triphosphate (NTP) including α-NTP, and inorganic phosphate (Pi), expressed relative to total phosphate (TP) or [PME+PDE] and converted to percentage, were obtained.
RESULTS: Compared to controls, both NAFLD groups had increased PDE/TP (p<0.001) and decreased Pi/TP (p=0.011). Non-NASH patients showed decreased PE/[PME+PDE] (p=0.048), increased GPC/[PME+PDE] (p<0.001), and normal NTP/TP and α-NTP/TP. Whereas, NASH patients had normal PE/[PME+PDE] and GPC/[PME+PDE], but decreased NTP/TP (p=0.004) and α-NTP/TP (p<0.001). The latter was significantly different between non-NASH and NASH (p=0.047) and selected as discriminating parameter, with area under the receiver-operating characteristics curve of 0.71 (95% confidence interval, 0.62-0.79). An α-NTP/TP cutoff of 16.36% gave 91% sensitivity and cutoff of 10.57% gave 91% specificity for NASH.
CONCLUSIONS: (31)P-MRS shows distinct biochemical changes in different NAFLD states, and has fair diagnostic accuracy for NASH.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenosine triphosphate; Liver fibrosis; Non-alcoholic steatohepatitis; Phosphorus metabolites; Simple steatosis

Mesh:

Substances:

Year:  2013        PMID: 24291241     DOI: 10.1016/j.jhep.2013.11.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Genetic and hormonal control of hepatic steatosis in female and male mice.

Authors:  Frode Norheim; Simon T Hui; Emre Kulahcioglu; Margarete Mehrabian; Rita M Cantor; Calvin Pan; Brian W Parks; Aldons J Lusis
Journal:  J Lipid Res       Date:  2016-11-03       Impact factor: 5.922

Review 2.  Diagnostic imaging in the management of patients with metabolic syndrome.

Authors:  Seo Rin Kim; Lilach O Lerman
Journal:  Transl Res       Date:  2017-11-22       Impact factor: 7.012

3.  Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease.

Authors:  Benjamin Pulli; Gregory Wojtkiewicz; Yoshiko Iwamoto; Muhammad Ali; Matthias W Zeller; Lionel Bure; Cuihua Wang; Yuri Choi; Ricard Masia; Alex R Guimaraes; Kathleen E Corey; John W Chen
Journal:  Radiology       Date:  2017-03-30       Impact factor: 11.105

Review 4.  Molecular aspects of fructose metabolism and metabolic disease.

Authors:  Mark A Herman; Morris J Birnbaum
Journal:  Cell Metab       Date:  2021-10-06       Impact factor: 27.287

5.  Contributions of Magnetic Resonance Imaging to Gastroenterological Practice: MRIs for GIs.

Authors:  Christopher G Roth; Dina Halegoua-De Marzio; Flavius F Guglielmo
Journal:  Dig Dis Sci       Date:  2018-05       Impact factor: 3.199

Review 6.  [Functional MR imaging of the liver].

Authors:  A Wibmer; R Nolz; M Trauner; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

7.  1H Magnetic Resonance Spectroscopy Predicts Hepatocellular Carcinoma in a Subset of Patients With Liver Cirrhosis: A Randomized Trial.

Authors:  Dan Wang; Yuehua Li
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

Review 8.  Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis.

Authors:  Rasha AlShaalan; Murad Aljiffry; Said Al-Busafi; Peter Metrakos; Mazen Hassanain
Journal:  Saudi J Gastroenterol       Date:  2015 Mar-Apr       Impact factor: 2.485

9.  Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.

Authors:  Stefan Traussnigg; Christian Kienbacher; Martin Gajdošík; Ladislav Valkovič; Emina Halilbasic; Judith Stift; Christian Rechling; Harald Hofer; Petra Steindl-Munda; Peter Ferenci; Fritz Wrba; Siegfried Trattnig; Martin Krššák; Michael Trauner
Journal:  Liver Int       Date:  2017-05-20       Impact factor: 5.828

10.  Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease.

Authors:  Stefan Traussnigg; Emina Halilbasic; Harald Hofer; Petra Munda; Tatjana Stojakovic; Günter Fauler; Karl Kashofer; Martin Krssak; Michael Wolzt; Michael Trauner
Journal:  Wien Klin Wochenschr       Date:  2020-09-15       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.